Core Insights - Medtronic is transforming its strategy in China from being an "innovative technology exporter" to a "local ecosystem builder" by focusing on five interconnected chains: innovation integration, local manufacturing, value co-creation, intelligent services, and collaborative supply chain [1][3] Local Manufacturing - Medtronic has invested in local production capabilities, exemplified by the Mazor XC spinal surgery robot, which is a localized version of its global Mazor X series, showcasing China's ability to produce high-end medical devices [3][4] - The "Genesis Electric Stapler," developed entirely in China, was brought from research to mass production within a year and is now used in over 500 hospitals domestically and has been exported globally [4] Innovation Integration - The Lantern left bundle branch pacing catheter, developed through collaboration with Chinese clinicians, represents a significant innovation that will serve global markets, highlighting China's role in driving global medical advancements [5] - Medtronic's first localized product in neurointervention, the "Mei An Xin" coil, has been designed to meet the needs of Chinese patients and is already implanted in 28 provinces [5] Collaborative Ecosystem - Medtronic's "value co-creation chain" and "collaborative supply chain" strategies are evident in its partnerships, such as the RDN technology for hypertension treatment, which is set to be the first device approved in the U.S., EU, and China simultaneously [6] - The company has developed nearly 7,000 supply chain partners in China, with projected procurement of approximately 5 billion RMB in the fiscal year 2025, emphasizing local supplier integration [6][7] Intelligent Services - Medtronic is establishing a digital healthcare innovation base in Beijing, set to open by the end of 2025, focusing on remote management and intelligent follow-up solutions to enhance the healthcare ecosystem in China [8] - The company's long-term commitment to the Chinese market is reflected in its strategy to foster cooperation and shared progress in medical innovation [9]

报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月7日，波士顿科学（纽约证券交易所代码：BSX）宣布， 完成对 血管内超声系统开发商 SoniVie的收购。 此次收购使波士顿科学正式进入竞争激烈的肾动脉去神经术（Renal Denervation, RDN）领域。 # 收购详情 波士顿科学此前已是SoniVie的战略投资者，持有其约 10%的股权 。此次交易中，波士顿科学为收购尚 未持有的 90%股权支付了约 3.6亿美元 的预付款 。 此外，交易还包括最高达 1.8亿美元 的潜在监管里程碑付款 。不考虑股权因素，波士顿科学将此次交易 估值为4亿美元预付款加上2亿美元里程碑付款， 总计6亿美元 （约合43亿人民币）。 波士顿科学全球副总裁及心脏介入事业部总裁Lance Bates 表示，"经肾动脉去交感神经术治疗高血压是 一项激动人心的医学进步，有望造福数百万患者。这一疗法已在当前临床试验与持续开展的研究中收获了 积极成果。 我们相信，TIVUS 系统能为我们丰富的介入产品组合增添针对高血压患者的微创疗法，为这 一领域的未来发展提供更多可能。 " # TIVUS血 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 在医疗科技深度融合临床实践的当下，医学装备行业正经历技术与应用的双重跃迁。从精准诊断到微创治疗，从智能康复到个性化医疗，医学装备的每一次 技术突破都直接影响着医疗质量与患者预后。然而，行业的高速发展不仅带来了创新机遇，也伴随着标准化、适应性落地和成本控制等多重挑战。 在这一背景下， 2025中国医学装备大会暨医学装备展览会 成为观察行业动向的重要窗口。2025年3月13日至16日，重庆国际博览中心将汇聚 800多家企 业 ，展示超过 1000件创新产品 。这不仅是一场技术竞演，更是对医疗装备未来走向的深度探讨——哪些技术能够真正提升临床价值？国产创新如何突破市 场壁垒？政策与产业如何协同推动高质量发展？答案，或将在这次行业盛会上逐步揭晓。 # 会议信息 此次参会的龙头企业包括 强生、雅培、美敦力、直观复星、上海微创机器人、迈瑞医疗、东软医疗、GE医疗、西门子医疗、飞利浦、罗氏、碧迪医疗 等。 34大 专业展区，覆盖了从基础到前沿的每一个细分领 ...